期刊文献+

纤溶药物在脑出血治疗中的运用 被引量:3

下载PDF
导出
摘要 脑出血是一种常见病,具有病死率高和致残率高等特点,重症患者发病后30 d内的病死率可高达30%~40%。脑出血治疗方案的选择主要需考虑出血部位、出血量及颅内高压程度等因素,治疗方法主要包括保守治疗、微创血肿穿刺术联合溶栓药物灌洗术、脑室外引流术、开颅血肿清除或联合去骨减瓣压术等。然而,无论采用哪种治疗方法,血肿残留均非常常见,而且部分患者的血肿程度介于开颅手术或非手术治疗指征之间。因此,针对中小量脑实质血肿及脑室出血,溶栓药物辅助微创外科手术的临床应用日益广泛,特别是新型、高效、快捷的溶栓药物重组纤溶酶原激活剂(rt-PA )的应用,取得显著疗效。本文对溶栓药物在脑出血治疗中的应用现状、进展进行综述。
作者 刘备 程远
出处 《检验医学与临床》 CAS 2014年第5期690-692,716,共4页 Laboratory Medicine and Clinic
  • 相关文献

参考文献32

  • 1Collen DyLijnen HR.Tissue-type plasminogen activator:ahistorical perspective and personal account[J].J ThrombHaemostas,2004,2(4):541-546. 被引量:1
  • 2Bell WR.Present-day thrombolytic therapy:therapeutic a-gents-pharmacokinetics and pharmacodynamics[J]. RevCardiovase Med,2002,3(12):34-44. 被引量:1
  • 3袁桂清.血栓性疾病已成为威胁人类健康和生命的重要疾病[J].中华检验医学杂志,2004,27(8):487-487. 被引量:13
  • 4刘晓宇,王憬惺.Reteplase—第3代基因重组纤溶酶原激活物[J].中国输血杂志,2000,13(2):127-130. 被引量:12
  • 5Mihara H,Sumi H,Akazawa T,et al.Fibrinolytic enzymeextracted from the earthworm[J].Thromb Haemostas,1983,50(1):258-263. 被引量:1
  • 6崔丽,董明胜.蛹虫草纤溶酶的分离纯化、酶学性质及溶栓抗栓作用研究[D].南京:南京农业大学,2008. 被引量:2
  • 7Hoff JT,Xi G.Brain edema from intracerebral hemor-rhage[J].Acta Neurochir Suppl(Wien),2003 ?86(1):11-15. 被引量:1
  • 8Hua Y,Nakamura T,Keep RF?et al.Long-term effects ofexperimental intracerebral hemorrhage:the role of iron[J].J Neurosurg,2006,104(2):305-312. 被引量:1
  • 9Keep RF,Xiang J,Ennis SR,et al.Blood-brain barrierfunction in intracerebral hemorrhage[J].Acta NeurochirSuppl(Wien),2008,105(1):73-77. 被引量:1
  • 10Mould WA,Carhuapoma JR,Muschelli J,et al.Minimallyinvasive surgery plus recombinant tissue-type plasmino-gen activator for intracerebral hemorrhage evacuation de-creases perihematomal edema[J].Stroke,2013,44(3):627-634. 被引量:1

二级参考文献10

  • 1Martin U,Bader R,Bohm E,et al.BM06. 022: a novel recombinant plasminogen activator[].Cardiovascular Drugs.1993 被引量:1
  • 2INJECT Study Group.Retevase, Reteplase, recombinant.Physicians Desk Reference, Gaithersburg[].Medical Economics.1998 被引量:1
  • 3Kanamasa K,Watanabe I,Cercek B,et al.Selective decrease in lysis of old thrombi offers rapid administration of tissue type plasminogen activator[].Journal of the American College of Cardiology.1989 被引量:1
  • 4Martin U,von Mollendorff E,Akpan W.Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06. 022 in healthy volunteers[].Thrombosis and Haemostasis.1991 被引量:1
  • 5Martin U,Dalchau H,Sponer G,et al.Effects of the novel recombinant plasminogen activator BM 06. 022 on platelets and bleeding time in rabbits[].Platelets.1992 被引量:1
  • 6Smalling RW,Bode C,Kalbfleisch J,et al.More rapid, complete, and stable coronary thrombolysis with bolus administration of Reteplase compared with Alteplase infusion in AMI[].Circulation.1995 被引量:1
  • 7Versraete M.Lijnen H, Collen D.Thromblytics agents in development[].Drugs.1995 被引量:1
  • 8Martin U & von Mollendorff E.Dose-ranging study of the novel recombinant plasminogen activator BM 06. 022 in healthy volunteers[].Clinical Pharmacology and Therapeutics.1991 被引量:1
  • 9INJECT Study Group.Randomized, double-blind comparison of Reteplase double-bolus administration with streptokinase in actue myocardial infarction trial to investigate equivalence[].The Lancet.1995 被引量:1
  • 10Martin U,Fischer S,Konert U,et al.Coronary thrombolytics properties of novel recombinant plasminogen activator BM 06. 022 in canine model[].J Cardiovasc Pharmacol.1991 被引量:1

共引文献22

同被引文献22

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部